普芦卡必利和莫沙必利分别联用小剂量聚乙二醇治疗老年难治性功能性便秘的短期疗效比较

发布时间：2018-06-08 04:30

本文选题：难治性功能性便秘 + 老年　；参考：《重庆医学》2017年20期

【摘要】：目的比较普芦卡必利、莫沙必利分别联用小剂量聚乙二醇治疗老年难治性功能性便秘的短期疗效。方法对2014年5月至2016年2月在该院门诊诊治的老年难治性功能性便秘患者90例进行回顾性分析。入选病例分为两组,每组45例。普芦卡必利组:琥珀酸普芦卡必利片,2mg,每日1次;莫沙必利组:枸橼酸莫沙必利胶囊,5mg,每日3次。两组均联用复方聚乙二醇电解质散(PEG)13.125g,每日2次,疗程4周。观察两组患者首次排便和排便困难缓解时间、每周完全自发排便(SCBM)平均次数、排便困难、大便性状、不良反应及生命质量的变化。结果两组慢传输型、排便障碍型的治疗有效率比较,差异均有统计学意义(P0.05),混合型差异无统计学意义(P0.05)。与莫沙必利组比较,普卢卡必利组首次排便时间和排便困难缓解时间均较短,差异有统计学意义(P0.05)。治疗后4周,两组患者SCBM3次,普卢卡必利组次数更多;普芦卡必利组排便困难改善更为明显,差异有统计学意义(P0.05)。大便性状改善组间比较,差异无统计学意义(P0.05)。两组总有效率比较差异有统计学意义(P0.05),不良反应发生率比较差异无统计学意义(P0.05)。治疗后4周,两组患者便秘患者生存质量自评量表(PAC-QOL)评分的总均分均有下降,普芦卡必利组降低更为明显,差异有统计学意义(P0.05)。结论普芦卡必利+PEG治疗老年难治性功能性便秘起效更快,且在总体疗效及生命质量改善方面有优势,尤适用于慢传输型和排便障碍型。
[Abstract]:Objective to compare the short-term efficacy of prucapride and mosapride in the treatment of refractory functional constipation in the elderly. Methods from May 2014 to February 2016, 90 elderly patients with refractory functional constipation were analyzed retrospectively. The patients were divided into two groups, 45 cases in each group. Prucapride group: 2 mg of prucapride succinate tablets, once a day; mosapride group: 5 mg of mosapride citrate capsule, 3 times a day. Both groups were treated with compound polyethylene glycol electrolyte powder (PEG) 13.125 g twice a day for 4 weeks. The first defecation and defecation difficulty relief time, the average times of complete spontaneous defecation per week, defecation difficulty, defecation character, adverse reaction and quality of life were observed in the two groups. Results the effective rates of slow transmission and defecation disorder in the two groups were significantly higher than those in the control group (P 0.05), but there was no significant difference between the mixed type and the control group (P 0.05). Compared with mosapride group, the first defecation time and defecation difficulty relief time were shorter in Pulucapride group, and the difference was statistically significant (P 0.05). Four weeks after treatment, SCBM3 times in the two groups, Prucapride group more times, the improvement of defecation difficulty was more obvious in the prucapride group, the difference was statistically significant (P 0.05). There was no significant difference between the two groups in improving defecation traits (P 0.05). There was significant difference in the total effective rate between the two groups (P 0.05), but there was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). At 4 weeks after treatment, the total mean score of PAC-QOLscore of patients with constipation in both groups was decreased, especially in the prucapride group, and the difference was statistically significant (P 0.05). Conclusion prucapride PEG is more effective in the treatment of refractory functional constipation in the elderly, and has advantages in improving the overall curative effect and quality of life, especially for slow transit type and defecation disorder type.
【作者单位】：广东省河源市源城区人民医院消化内科;
【分类号】：R574.62

【相似文献】